Inflammatory Mediator Profiling Reveals Immune Properties of Chemotactic Gradients and Macrophage Mediator Production Inhibition during Thioglycollate Elicited Peritoneal Inflammation

Table 1

Concentrations and ratios of inflammatory mediators in exudates and plasma on day 1 after thioglycollate treatment in vivo*.

	Exudates; (A, 𝑛=3)	Plasma; (B, 𝑛=4)	Ratio of mean value; between A and B
FGF-9	2.60±0.26	2.23±0.51	1.17
KC/GRO	11.33±2.33	335.00±127.05	0.03
IFN-γ	14.00±1.53	10.90±3.52	1.28
IP-10	114.00±16.70	117.50±5.72	0.97
IL-1α	170.33±3.53	282.00±71.17	0.60
IL-6	18.67±0.67	14.65±4.24	1.27
IL-17A	6.23±0.92	2.81±1.62	2.22
Lymphotactin**	38.70±1.45	98.00±5.28	0.40
MIP-1β**	3373.33±274.73	610.25±105.45	5.53
MIP-2	26.70±0.67	35.75±10.38	9.75
MCP-1	1069.33±341.10	364.25±65.35	2.94
MCP-3	2193.33±579.55	970.50±64.64	2.26
MCP-5	89.00±21.50	69.25±1.65	1.29
OSM	260.00±17.32	231.25±79.01	1.12
SCF	707.00±21.55	1084.50±198.52	0.65
RANTES***	0.09±0.01	0.04±0.00	2.17
TIMP-1**	38.67±3.18	7.40±0.85	5.23
TNF-α**	71.67±2.96	35.75±2.93	2.01
VEGF-A	820.33±18.44	943.00±109.18	0.87

*The unit for all concentrations is pg/mL, except FGF-9 and TIMP-1 as ng/mL.
** 𝑃<0.001.
*** 𝑃<0.05.
All other samples 𝑃>0.05.